Results 71 to 80 of about 424,390 (258)
A Novel Pak1 Activator Ameliorates ER Stress for HFpEF Therapy
Chronic metabolic stress is a major contributor to HFpEF progression. Under prolonged metabolic stress, Pak1 activity becomes impaired, contributing to disrupted ER proteostasis, cardiomyocyte apoptosis, fibrosis, and diastolic dysfunction. Mechanistically, Pak1 overexpression activates the ERK1/2–MNK1–eIF4E signaling axis, promotes translational ...
Honglin Xu +17 more
wiley +1 more source
The aim of this single‐centre retrospective observational study was to evaluate the safety, tolerability, and efficacy of an in‐class combination therapy switch from bosentan plus sildenafil to ambrisentan plus tadalafil in children with pulmonary ...
Cara Morgan +7 more
doaj +1 more source
The characteristics of patients with anal fistula cancer included a higher proportion of men, younger age, more smokers, and tumor‐related characteristics, including more advanced local progression. Surgical characteristics included a lower rate of minimally invasive surgery, a higher proportion of total pelvic exenterations, and longer postoperative ...
Nobuaki Hoshino +5 more
wiley +1 more source
Group 1 of PAH patients encompasses patients with a diverse underlying etiological condition, having histological modifications that can affect gas exchange across the alveolar-capillary membrane, as reflected by decreased DLCO.
Effrosyni Dima +12 more
doaj +1 more source
According to multivariable analysis conducted using a hierarchical logistic regression model, using VHH as the reference group, the odds ratios for mortality by hospital volume category were as follows: VLH, 2.70 (p < 0.0001); LH, 1.72 (p = 0.052); MH, 1.70 (p = 0.034); and HH, 1.43 (p = 0.173).
Soji Ozawa +8 more
wiley +1 more source
In this multicenter prospective study of 158 working‐age patients undergoing curative‐intent surgery for gastric or esophageal cancer, 78.5% were working at 18 months. Postoperative appetite loss, financial difficulties, and ≥ 10% weight loss at 6 months were associated with non‐working status.
Kentaro Goto +18 more
wiley +1 more source
Targeted vasopeptide therapies have significantly advanced the management of pulmonary arterial hypertension (PAH). However, due to insufficient preclinical evidence regarding the involvement of the endothelin-1 (ET-1) pathway in chronic thromboembolic ...
Benchenouf Feriel +16 more
doaj +1 more source
DDAH1 regulates apoptosis and angiogenesis in human fetal pulmonary microvascular endothelial cells
Nitric Oxide (NO) is an endogenous pulmonary vasodilator produced by endothelial NO synthase (eNOS). Asymmetric dimethyl L‐arginine (ADMA) is an endogenous inhibitor of eNOS activity.
Jennifer K. Trittmann +3 more
doaj +1 more source
This multicenter propensity score‐matched study of 3213 patients compared intracorporeal (IA) and extracorporeal (EA) anastomosis during minimally invasive colectomy. IA was associated with a significantly lower incidence of intraoperative blood loss ≥ 200 mL (2.5% vs.
Takuya Takami +9 more
wiley +1 more source
Sarcopenia in Patients with Chronic Thromboembolic Pulmonary Hypertension
Background: Sarcopenia, or loss of skeletal muscle mass, has been associated with poor outcomes (e.g., functional decline, increased mortality, and low quality of life), but its role in CTEPH remains unclear.
Steven Hopkins +8 more
doaj +1 more source

